DTME(二硫基双马来酰亚胺乙烷)
DTME(二硫基双马来酰亚胺乙烷)
Thermo Scientific™

DTME(二硫基双马来酰亚胺乙烷)

Thermo Scientific Pierce DTME 是一种中等长度的马来酰亚胺交联剂,通过还原间隔臂中心的二硫键实现巯基(例如蛋白或肽半胱氨酸)之间的可逆共价偶联。DTME 的特点:•反应性基团:马来酰亚胺(两端了解更多信息
Have Questions?
货号数量
2233550 mg
货号 22335
价格(CNY)
5,329.00
飞享价
Ends: 31-Dec-2025
6,803.00
共减 1,474.00 (22%)
Each
添加至购物车
数量:
50 mg
请求批量或定制报价
价格(CNY)
5,329.00
飞享价
Ends: 31-Dec-2025
6,803.00
共减 1,474.00 (22%)
Each
添加至购物车
Thermo Scientific Pierce DTME 是一种中等长度的马来酰亚胺交联剂,通过还原间隔臂中心的二硫键实现巯基(例如蛋白或肽半胱氨酸)之间的可逆共价偶联。

DTME 的特点:

反应性基团:马来酰亚胺(两端)
可与以下基团发生反应:巯基
•长 (13.3A) 的可切割巯基-巯基交联剂,由马来酰亚胺基团和 11 原子二硫化物间隔臂组成
• 不溶于水—首先溶于 DMF 或 DMSO 中,然后添加至水性反应缓冲液
•可通过 DTT、TCEP 或其他还原剂还原二硫化物间隔臂进行切割

产品参考:
交联剂应用指南 -- 检索本产品的最新参考文献

相关产品
BMH(双马来酰亚胺基己烷)
仅供科研使用。不可用于诊断程序。
规格
细胞渗透性
描述DTME
形式实心
标记方法化学标记
分子量312.36
聚乙二醇化
产品线Pierce
数量50 mg
反应一部分马来酰亚胺
运输条件环境
溶解度DMF、DMSO
间隔臂长13.3 Å
水溶性
化学反应性巯基-巯基
可裂解用硫醇
交联剂类型同型双功能团试剂
产品规格标准
产品类型交联剂
间隔子中等(10 至 30 Å)
Unit SizeEach
内容与储存
接收后,请在 4°C 下干燥储存。

常见问题解答 (FAQ)

Can you provide the shelf-life for DTME (dithiobismaleimidoethane)?

DTME (dithiobismaleimidoethane) is covered under our general 1-year warranty and is guaranteed to be fully functional for 12 months from the date of shipment, if stored as recommended. Please see section 8.1 of our Terms & Conditions of Sale (https://www.thermofisher.com/content/dam/LifeTech/Documents/PDFs/Terms-and-Conditions-of-Sale.pdf) for more details.

Find additional tips, troubleshooting help, and resources within our Protein Purification and Isolation Support Center.

引用和文献 (5)

引用和文献
Abstract
Nedd4-1 and beta-arrestin-1 are key regulators of Na+/H+ exchanger 1 ubiquitylation, endocytosis, and function.
Authors:Simonin A, Fuster D
Journal:J Biol Chem
PubMed ID:20855896
'The ubiquitously expressed mammalian Na(+)/H(+) exchanger 1 (NHE1) controls cell volume and pH but is also critically involved in complex biological processes like cell adhesion, cell migration, cell proliferation, and mechanosensation. Pathways controlling NHE1 turnover at the plasma membrane, however, are currently unclear. Here, we demonstrate that NHE1 undergoes ubiquitylation ... More
The extreme C terminus of the ABC protein DrrA contains unique motifs involved in function and assembly of the DrrAB complex.
Authors:Zhang H, Pradhan P, Kaur P
Journal:J Biol Chem
PubMed ID:20876527
'Two novel regulatory motifs, LDEVFL and C-terminal regulatory Glu (E)-rich motif (CREEM), are identified in the extreme C terminus of the ABC protein DrrA, which is involved in direct interaction with the N-terminal cytoplasmic tail of the membrane protein DrrB and in homodimerization of DrrA. Disulfide cross-linking analysis showed that ... More
Association of Rho-associated protein kinase 1 with E-cadherin complexes is mediated by p120-catenin.
Authors:Smith AL, Dohn MR, Brown MV, Reynolds AB
Journal:Mol Biol Cell
PubMed ID:22031287
The dynamic functional linkage of cadherins with the underlying actin cytoskeleton is tightly regulated to achieve proper cell-cell adhesion. p120-catenin (p120) regulates both cadherin stability and actin dynamics, but the relationship between these two functions remains unclear. Using a novel proteomic approach called reversible cross-link immunoprecipitation, or ReCLIP, we previously ... More
Claudin-2 forms homodimers and is a component of a high molecular weight protein complex.
Authors:Van Itallie CM, Mitic LL, Anderson JM
Journal:J Biol Chem
PubMed ID:21098027
Tight junctions are multiprotein complexes that form the fundamental physiologic and anatomic barrier between epithelial and endothelial cells, yet little information is available about their molecular organization. To begin to understand how the transmembrane proteins of the tight junction are organized into multiprotein complexes, we used blue native-PAGE (BN-PAGE) and ... More
Strategies for stabilizing superoxide dismutase (SOD1), the protein destabilized in the most common form of familial amyotrophic lateral sclerosis.
Authors:Auclair JR, Boggio KJ, Petsko GA, Ringe D, Agar JN
Journal:Proc Natl Acad Sci U S A
PubMed ID:21098299
Amyotrophic lateral sclerosis (ALS) is a disorder characterized by the death of both upper and lower motor neurons and by 3- to 5-yr median survival postdiagnosis. The only US Food and Drug Administration-approved drug for the treatment of ALS, Riluzole, has at best, moderate effect on patient survival and quality ... More